Patents Examined by Zohreh Fay
  • Patent number: 9889104
    Abstract: The present invention provides a prophylactic and/or therapeutic drug for diabetes, which contains 8-[2-(2-pentyl-cyclopropylmethyl)-cyclopropyl]-octanoic acid (DCP-LA) as an active ingredient, particularly a prophylactic and/or therapeutic drug for diabetes, which promotes sugar intake into the cells, and the like.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: February 13, 2018
    Assignee: Nishizaki Bioinformation Research Institute
    Inventor: Tomoyuki Nishizaki
  • Patent number: 9872865
    Abstract: This invention relates to methods and compositions for use improving cell viability, particularly neural cell viability, and more particularly to methods and compositions for use improving cell viability by reducing reactive oxygen metabolite-mediated oxidative damage in a cell, regulating redox homeostasis in a cell, or reducing mitochondrial dysfunction in a cell. The invention further relates to the administration of the bile acid tauroursodeoxycholic acid (TUDCA) in combination with phenylbutyric Acid (PBA) to improve cell viability, and treat at least one symptom associated with, prevent the time of onset of, or slow the development of a disease related to oxidative stress.
    Type: Grant
    Filed: December 24, 2013
    Date of Patent: January 23, 2018
    Assignee: Amylyx Pharmaceuticals Inc.
    Inventors: Joshua Cohen, Justin Klee
  • Patent number: 9861593
    Abstract: Method for the treatment or prophylaxis of dry eye disorders by the administration of alkylamino-polyhydroxyalkanes and compositions thereof.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: January 9, 2018
    Assignee: Dynamis Pharmaceuticals, Inc.
    Inventors: Alice Marcy, Annette Tobia
  • Patent number: 9844530
    Abstract: This invention generally relates to methods of treatment of glaucoma and symptomatic relief of conjunctival inflammation. An ophthalmic solution comprising cannabinoids for the treatment of glaucoma and an ophthalmic solution comprising cannabinoids for these purposes are disclosed. Cannabinoids are selected to achieve the specific purpose of the respective ophthalmic solution.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: December 19, 2017
    Assignee: Axim Biotechnologies, Inc.
    Inventors: George Anastassov, Lekhram Changoer
  • Patent number: 9820989
    Abstract: The present invention relates to a method of treating ophthalmic diseases and conditions, e.g. diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, etc., in a subject comprising administering to said subject a therapeutically effective amount of at least one compound of formula I or a prodrug, pharmaceutically acceptable salt, racemic mixtures or enantiomers of said compound. The compounds of formula I are capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: November 21, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Clarence E. Hull, III, Thomas C. Malone
  • Patent number: 9820954
    Abstract: The present invention is directed methods of lowering intraocular pressure in a patient suffering from elevated intraocular pressure or glaucoma and treating ocular disease by administering a drug to the periorbital skin of the patient.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: November 21, 2017
    Assignee: JENIVISION INC.
    Inventors: David F. Woodward, Weizhen Wang
  • Patent number: 9814702
    Abstract: The present application relates to topical formulations comprising Compound-I or its free base, and a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, and a combination thereof, for treating ocular neovascularization. The present application also relates to pharmaceutical compositions comprising particles of Compound-I or its free base, and suspension formulations comprising the particle compositions of Compound-I or its free base.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: November 14, 2017
    Assignee: PanOptica, Inc.
    Inventors: David P. Bingaman, Paul G. Chaney, Martin B. Wax
  • Patent number: 9814695
    Abstract: This invention generally relates to an ophthalmic solution comprising cannabinoids for the treatment of glaucoma. Also disclosed is an ophthalmic solution comprising cannabinoids for symptomatic relief of conjunctival inflammation. Cannabinoids are selected to achieve the specific purpose of the respective ophthalmic solution.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: November 14, 2017
    Assignee: Axim Biotechnologies, Inc.
    Inventors: George Anastassov, Lekhram Changoer
  • Patent number: 9801891
    Abstract: Disclosed herein are compositions for lowering intraocular pressure (IOP) of an eye comprising a combination IOP-lowering agents bimatoprost, brimonidine, and timolol. Further disclosed are methods for reducing IOP in the eye of a subject.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: October 31, 2017
    Assignee: ALLERGAN, INC.
    Inventor: Chetan P. Pujara
  • Patent number: 9795537
    Abstract: Methods to enable a visual check on the mixing proper pharmaceutical compounding kits. The methods include providing a kit with a colored inactive to be added to the mixture. When the mixture is uniform or resembles a predetermined color, the mixture is assumed to be properly mixed.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: October 24, 2017
    Inventors: Austin Bonderer, Clark Levi
  • Patent number: 9795614
    Abstract: The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: October 24, 2017
    Assignee: Topokine Therapeutics, Inc.
    Inventors: Cynthia L. Grosskreutz, Louis R. Pasquale, Michael S. Singer, Murat V. Kalayoglu
  • Patent number: 9789078
    Abstract: The present invention relates to cyclic or repeated use of the ingenol mebutate for topical treatment of actinic keratosis lesions. Generally speaking, the present invention comprises a first ingenol mebutate treatment cycle and a second ingenol mebutate treatment cycle, wherein the first treatment cycle topically treats a treatment area with a topical gel formulated with ingenol mebutate at a selected dosage strength for a specified treatment regimen, and the second ingenol mebutate treatment cycle comprises topically re-treating the treatment area with the same topical ingenol mebutate gel for the same specified treatment regimen, if following the first treatment cycle, the treatment area failed to clear or failed to remain clear of AK lesions. The present invention further relates to spot or individual lesion therapy in the treatment area following the topical bi-cyclic therapy with ingenol mebutate.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: October 17, 2017
    Assignee: LEO Laboratories Limited
    Inventor: Kirsten Norrelund
  • Patent number: 9783688
    Abstract: The present invention relates to a lens care solution having 0.001 to about 5 weight percent of a low molecular weight amine of the general formula: where R1, R2, R3 and R4 are —H or low molecular weight radicals, and R5 is a low molecular weight radical, or salt thereof; an effective amount of a tonicity agent; and the balance water.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: October 10, 2017
    Assignee: FXS VENTURES, LLC
    Inventor: Francis X. Smith
  • Patent number: 9782397
    Abstract: There is provided inter alia a compound which is an NK-1 receptor antagonist for use in the treatment or prevention of CNV. There is also provided a compound which is an NK-1 antagonist for use in the treatment of chemical burns of the eye particularly alkali burns of the eye. There is also provided a pharmaceutical composition for topical administration to the eye comprising an NK-1 antagonist and an antibiotic agent.
    Type: Grant
    Filed: July 4, 2012
    Date of Patent: October 10, 2017
    Assignee: IRBM SCIENCE PARK S.P.A.
    Inventor: Giulio Ferrari
  • Patent number: 9775861
    Abstract: An ophthalmic composition of water soluble ingredients provides additional moisture to the eye by promoting moisture absorption from the air and providing long lasting relief. The composition can include two groups of ingredients, one a liquid and the other a solid. Together, the ingredients form a substance that ranges from a liquid to a gel. Benefits of such composition include longer lasting symptom relief with less applications and increased moisture production.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: October 3, 2017
    Inventors: Paul S. Jensen, Isaiah U. Lieberman
  • Patent number: 9775796
    Abstract: A skin composition includes between 5% and 95% of polyethylene glycol and between 5% and 95% of glycereth. The composition is a gel that is formulated for application to an individual's skin.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: October 3, 2017
    Inventors: Paul S. Jensen, Isaiah U. Lieberman
  • Patent number: 9770447
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: July 12, 2016
    Date of Patent: September 26, 2017
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker
  • Patent number: 9770500
    Abstract: Provided herein are methods for ameliorating the pathophysiology cysteine protease exotoxin comprising the step of administering to said individual an effective dose of an S-nitrosylating agent and an inositol phosphate or analog thereof.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: September 26, 2017
    Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, CASE WESTERN RESERVE UNIVERSITY
    Inventors: Tor C. Savidge, Jonathan Stamler
  • Patent number: 9750685
    Abstract: The present invention is directed to ophthalmic devices that are loaded with therapeutic agent. The devices provide prolonged release of the therapeutic agent to the eye. The ophthalmic devices are typically formed of an ophthalmic material that is particularly desirable for the loading of therapeutic agent and/or the therapeutic agent is typically particularly desirable for loading to the ophthalmic material.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: September 5, 2017
    Assignee: NOVARTIS AG
    Inventors: Brett E. Thomes, Stephen J. Van Noy, Chi-Chun Tsai
  • Patent number: 9750684
    Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: September 5, 2017
    Assignee: Nicox Ophthalmics, Inc.
    Inventors: Mark Barry Abelson, Matthew J. Chapin, Paul Gomes, George Minno, Jackie Nice